logo
Earth-Like Planets May Be ‘Abundant' Around Red Dwarfs, Scientists Say

Earth-Like Planets May Be ‘Abundant' Around Red Dwarfs, Scientists Say

Forbes06-07-2025
This artist's impression shows a sunset seen from the super-Earth Gliese 667 Cc. Astronomers have ... More estimated that there are tens of billions of such rocky worlds orbiting faint red dwarf stars in the Milky Way alone.
There could be potentially hundreds of Earth-like planets close to the solar system, according to a new study that has found them to be common around the most typical kind of star.
Red dwarf stars — low-mas stars about a tenth to a fifth the mass of the sun — make up about 80% of the stars in the Milky Way, according to the European Southern Observatory. It's also thought that 20 out of the 30 stars near Earth are red dwarfs, including the closest star, Proxima Centauri, which was recently discovered to have potentially two planets in orbit.
Now, results from a new project called CARMENES have led to the identification of four new exoplanets — and a powerful new insight into where more are likely to be found.
Four New Exoplanets
An exoplanet is a planet that orbits a star other than the sun. Using an instrument called CARMENES at the Calar Alto Observatory near Almería, Spain, astronomers studied 15 red dwarf stars and discovered four new planets. Three of the planets were Earth-sized, while one was 14 times larger.
Extrapolating that data in a new paper published in Astronomy & Astrophysics shows that stars with less than 16% of the star's mass have, on average, about two planets that are less than three times the mass of Earth.
'Quite Remarkable' Findings
The discovery is limited to small planets — large planets appear to be rare around red dwarfs. 'It is quite remarkable how often small planets occur around very low-mass stars,' said lead author Dr Adrian Kaminski from the Königstuhl Observatory at the Center for Astronomy at Heidelberg University, Germany. 'This suggests that low-mass stars tend to form smaller planets in close orbits.'
Red Dwarves And 'Earth 2.0'
Of the 5,000 exoplanets discovered so far, none is a twin of Earth in terms of the type of star it orbits or its mass, radius and surface temperature. However, aside from orbiting a red dwarf star, the three small planets discovered using CARMENES do meet other criteria.
'Small, rocky planets in the so-called habitable zone – the area around a star where water could exist in liquid form – are potential candidates for habitable worlds,' said Prof. Dr Andreas Quirrenbach, director of the Königstuhl Observatory. He added that since they're common and long-lived, red dwarf stars could provide stable environments for the development of life.
Wishing you clear skies and wide eyes.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This Ancient Roman Artifact Is Also a 453 Million-Year-Old Fossil
This Ancient Roman Artifact Is Also a 453 Million-Year-Old Fossil

Gizmodo

time18 hours ago

  • Gizmodo

This Ancient Roman Artifact Is Also a 453 Million-Year-Old Fossil

Despite how Ross' paleontology career is treated by his companions in Friends, there's something special about finding the remains of creatures that lived millions if not billions of years before us. In fact, humanity's interest in paleontology isn't a modern development. Ancient Romans were just as fascinated by fossils. According to the ancient Roman historian Suetonius, Emperor Augustus established the first known paleontological museum at his villa on the island of Capri, where he showcased the bones of ancient 'giants' and 'monsters.' While paleontologists have yet to uncover such fantastical remains, a study published Thursday in the journal Science describes something that, in my opinion, is even more special—an ancient Roman amulet crafted from the fossil of a critter that lived between 453 and 460 million years ago. The researchers claim that the artifact 'represents the first documented trilobite in the Roman world and the earliest known reference to this fossil group—and the intentional manipulation of a trilobite specimen—in all of classical antiquity,' they wrote in the study. Trilobites are a group of marine arthropods that existed between 521 and 251 million years ago. It's also the 'third trilobite in the global archaeological record to have been collected and used by people over a thousand years ago,' they added. The rare artifact came to light in a Roman settlement in northwestern Spain called A Cibdá of Armea that existed from the first to the third century CE. The researchers suggest that the fossil itself originated in shale outcrops over 267 miles (430 kilometers) away from the Roman settlement. The trilobite likely reached the settlement via trade or as the property of someone from central Lusitania (a Roman province in Spain) moving to the region. Either way, someone clearly altered the fossil. 'The Armea trilobite fragment unquestionably shows evidence of anthropic work, particularly on the underside and left side of the piece,' the researchers explained. 'These marks do not affect the upper surface, which displays the characteristic articulated segments of a trilobite's dorsal exoskeleton. It seems clear that the person who modified the stone intended to leave that natural surface untouched, while simultaneously adapting the fossil to its new function.' According to the study, the modified fossil could have functioned as a game token, a part of a necklace or bracelet, a banded pendant on a metallic mount, or simply an object people carried in their bag or pocket. Regardless of how the trilobite was fashioned, it was likely kept for supernatural, propitiatory, or medicinal purposes and abandoned between the first and third centuries CE. 'It is plausible to consider that the Armea trilobite may have been perceived to hold magical and protective powers for its wearer, as is the case with fossils or even trilobites in other well-known archaeological contexts,' the researchers wrote. Coincidentally, archaeologists found the trilobite next to a bronze coin of Augustus. The discovery is a testament to the fact that humanity's curiosity for that which came before us is a universal trait that transcends cultures, borders, and even time itself. It stands as a reassuring reminder, especially in times like these—when the only thing everyone seems to agree on is our many differences.

The massive blackout in Spain, Portugal, and France exposed a global power crisis. Now what?
The massive blackout in Spain, Portugal, and France exposed a global power crisis. Now what?

Fast Company

time18 hours ago

  • Fast Company

The massive blackout in Spain, Portugal, and France exposed a global power crisis. Now what?

On the morning of April 28, large parts of Spain, Portugal, and southern France went dark. A massive blackout left millions without power, halting trains mid-track, cutting mobile networks, and rattling the foundation of one of Europe's most advanced energy grids. In the days that followed, experts and media outlets scrambled to explain what had happened. Was it a cyberattack? Human error? A structural failure? More than two months later, official investigations are ongoing. Early statements by the Spanish government confirmed that although no single cause has emerged, it wasn't a cyberattack. While the exact cause remains under review, one thing the energy industry agrees on is clear: This can't keep happening. 'A relentless cycle of evolution' 'Power systems are not only extremely complex, they are also in a relentless cycle of evolution—with new parts coming in and old ones going out—all while remaining stable and dependable 24/7,' says Richard Schomberg, special envoy for smart electrification at the International Electrotechnical Commission (IEC).

INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface
INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface

Yahoo

timea day ago

  • Yahoo

INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface

Graphene-based BCI demonstrates high-resolution brain decoding and mapping in patients undergoing tumor resection at the Manchester Centre for Clinical Neurosciences Initial four patient cohort has shown no safety concerns to date that would prevent the completion of this first-in-human study. BARCELONA, Spain, July 29, 2025--(BUSINESS WIRE)--INBRAIN Neuroelectronics today announced the interim analysis of findings from the world's first-in-human clinical study of its graphene-based brain-computer interface (BCI) technology. The study, sponsored by the University of Manchester and conducted at the Manchester Centre for Clinical Neurosciences (Northern Care Alliance NHS Foundation Trust), is evaluating the safety and functional performance of graphene-based electrodes when used during surgery for resection of brain tumors. The primary objective of the study (NCT06368310) is to assess the safety of INBRAIN's brain-computer interface (BCI) during brain tumor surgery. Secondary objectives include evaluating the quality of neural signals captured by the device, its ability to deliver targeted brain stimulation, the consistency of its performance throughout the procedure, and its overall suitability for use in the neurosurgical operating room. A total of 8 to 10 patients are expected to be enrolled to validate the safety and functional performance of the graphene-based BCI. The study design included an interim analysis after the first four patients had been recruited to ensure patient safety and data quality. Interim analysis of the results from the first cohort of four patients enrolled in the study demonstrated no device-related adverse events, a key component of the primary endpoint of the study. During awake language mapping, the device captured distinct high gamma activity linked to different phonemes, the smallest units of sound in speech, showcasing exceptional spatial and temporal resolution, even with micrometer-scale contacts. The ultra-thin, sub-micrometer graphene electrodes also proved compatible with commercially available, CE-marked electrophysiology systems, reliably recording real-time brain signals throughout the surgical procedures. "The ability to detect high-frequency neural activity with micrometer-scale precision opens new possibilities for understanding brain-tumor interactions and broader brain function in neuro-related disorders," said Mr. David Coope, Chief Investigator and Consultant Neurosurgeon at the Manchester Centre for Clinical Neurosciences, the Geoffrey Jefferson Brain Research Centre and the University of Manchester. "This technology could be transformative, not only for improving surgical outcomes but for unlocking new treatment pathways." Throughout the procedures, INBRAIN's BCI enabled high-resolution brain signal monitoring, addressing one of the most pressing challenges in neurosurgery: achieving precise tumor removal while preserving essential functions such as speech, movement, and cognition. The device was used in parallel with standard clinical monitoring tools, maintaining consistent performance across the surgical window. "This milestone demonstrates that graphene-based brain-computer interfaces can be deployed in the operating room and deliver a level of neural fidelity not achievable with traditional materials," said Carolina Aguilar, CEO and Co-Founder, INBRAIN Neuroelectronics. "We're moving toward a future where neurosurgeons and neurologists can rely on real-time, high-definition brain data to guide personalized interventions." INBRAIN's platform is powered by ultra-flexible, thin-film graphene semiconductors that conform more precisely to the brain surface than conventional strip electrodes. The BCI features high-density, multiscale, bidirectional contacts for superior decoding and modulation, and reduced graphene oxide (rGO) nanoporous matrices that enhance sensitivity and signal resolution. In preclinical studies, the GCI significantly outperformed platinum-based electrodes in detecting high gamma frequencies (80–130 Hz) critical for speech decoding, with statistical significance (p < 0.01). Clinical Advantages Graphene technology offers several benefits for neurosurgical procedures. It enhances surgical precision by enabling smaller and more densely packed electrodes, allowing surgeons to define and preserve critical functional areas during tumor resection. Its flexibility enables accurate decoding and mapping in anatomically complex or hard-to-access brain regions, including the walls of the tumor resection cavity. Additionally, the device's ability to decode high-frequency activity offers huge scientific opportunities including the potential to reveal in situ interactions between glioma cells and neurons, offering potential insights into new therapeutic targets for halting tumor progression. "We're not delivering incremental innovation, we're enabling entirely new capabilities," said Kostas Kostarelos, Co-Founder of INBRAIN and Chief Scientific Investigator of the study and Professor of Nanomedicine at the University of Manchester, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, and Programme Lead for the Next Generation Therapeutics Theme of the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC). "This convergence of advanced materials science, neuroscience, and AI is shaping the future of real-time, precision neurology." As the first safety study of a graphene-based neural interface in humans, this study marks a foundational step toward the development of BCI therapeutic systems for chronic neurological diseases, pioneering a new era of real-time, precision neurology. About INBRAIN Neuroelectronics INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world's first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit and follow us on LinkedIn. About Northern Care Alliance (NCA) Northern Care Alliance NHS Foundation Trust provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Our dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond, working together to save lives and improve lives. More information about the NCA can be found at About the National Institute for Health and Care Research (NIHR) The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government. About the NIHR Manchester Biomedical Research Centre (BRC) The NIHR Manchester Biomedical Research Centre (BRC) transforms scientific breakthroughs into diagnostic tests and life-saving treatments for patients. NIHR Biomedical Research Centres (BRCs) are collaborations between NHS organisations and universities. They bring together academics and clinicians to translate scientific discoveries into potential new treatments, diagnostics and technologies. Manchester BRC is hosted by Manchester University NHS Foundation Trust and The University of Manchester – in partnership with five NHS trusts; Blackpool Teaching Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Lancashire Teaching Hospitals NHS Foundation Trust, and the Northern Care Alliance NHS Foundation Trust. About The University of Manchester The University of Manchester is recognised globally for its pioneering research, outstanding teaching and learning, and commitment to social responsibility. The Russell Group institution is ranked the 6th best university in the UK and 38th in the world (Academic Ranking of World Universities). A truly international university, its community includes more than 44,000 students, 12,000 staff, and 500,000 alumni from 190 countries. Together, they are tackling the world's biggest challenges – the University's social and environmental impact is ranked in the top ten globally (Times Higher Education Impact Rankings). The University is a powerhouse of research and discovery; 25 Nobel laureates are among its former staff and students; and it was ranked fifth for research power – the quality and scale of research and impact – in the UK government's Research Excellence Framework (REF) 2021. The institution is the most popular in the UK for undergraduate applications (UCAS 2021 cycle), and it is the it is the most targeted university by the UK's leading employers (The Graduate Market, 2023). View source version on Contacts Media Kimberly HaKKH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store